Both nudge your own growth-hormone axis, but only one can be legally compounded in the US today. The honest difference, side by side.
Used to support muscle, recovery, and sleep quality.
Grade C, moderate clinical history as a GHRH analog; outcome data is limited.
Long-term outcome data is limited; effects vary with age and baseline.
Studied as a GH-axis stimulator for recovery and body-composition interest.
Grade C, modest human GHRH-analog data; long-acting (DAC) variants less characterized.
Long-term safety of the long-acting (DAC) form is poorly characterized in humans.
This is the cleanest example of our two-signal rule. Sermorelin and CJC-1295 are close cousins, both GHRH analogs that prompt your own GH release. The difference isn't really the molecule; it's the law. Sermorelin is 503A-eligible and available under a clinician; CJC-1295 was placed in Category 2 in 2023 and its nomination was later withdrawn, which leaves it in no FDA category at all — outside every enforcement-discretion policy — and it cannot be legally compounded. If you want the GH-axis effect through a legitimate route, the answer is Sermorelin.
Popularity doesn't change legality: CJC-1295 earns far more searches than it can legally fulfill. Neither is an anabolic shortcut, both are WADA-banned (S2), and Sermorelin's own outcome data is moderate. We route you to the legal option rather than the loud one.
They're close cousins, both GHRH analogs that stimulate your own growth hormone. The practical difference is regulatory: sermorelin is 503A-eligible and available under a clinician; CJC-1295's compounding nomination was withdrawn, leaving it in no FDA category and outside every enforcement-discretion policy, so it cannot be legally compounded in the US.
The FDA placed CJC-1295 in compounding Category 2 in September 2023; the nomination was later withdrawn, which leaves it in no category at all and outside every FDA enforcement-discretion policy. Either way it cannot be legally compounded. The legal GH-axis route is sermorelin.